• The company’s Cesium-131 based cancer treatments are effective, cheap and produce less side effects than other radiation.
• The company’s market cap is small in relation to its first big target market, prostate cancer.
• But there is another big market in treating brain cancer and a number of smaller additional applications.
• The company is displaying impressive revenue growth, margin improvement and it isn’t bleeding much cash anymore.

Source: IsoRay Likely Has Further To Rise – IsoRay, Inc. (NYSEMKT:ISR) | Seeking Alpha